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ABSTRACT
Introduction: The DAPA-CKD trial assessed
dapagliflozin in patients with chronic kidney
disease (CKD) with or without type 2 diabetes
(T2D). To aid interpretation of results, renal and
cardiovascular outcomes plus healthcare
resource utilization (HCRU) and costs were
assessed in a real-world population similar to
that of DAPA-CKD.
Methods: Henry
Ford
Health
System
(2006–2016) data were used to identify patients
with CKD stages 2–4 [estimated glomerular filtration rate (eGFR) 25–75 ml/min/1.73 m2 at
index and urine albumin-to-creatinine ratio
(UACR) 0–5000 mg/g; n = 22,251]. Included
patients had confirmatory eGFR C 90 days postindex and no kidney transplant or progression
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to end-stage kidney disease during 12 months
pre-index. The final population (n = 6557) was
stratified by UACR (0–29, 30–199 and
200–5000 mg/g; the last comprising the DAPACKD-like cohort). Patients were followed for
5 years post-index.
Results: Adverse clinical outcomes incidence
increased with UACR and was highest for the
DAPA-CKD-like cohort (UACR 200–5000 mg/g)
versus lower UACR categories (0–29 mg/g and
30–199 mg/g): renal composite outcome (progression to CKD stage 5, dialysis, transplant, C 50% sustained eGFR decline): 26.0%
versus 2.2% and 5.8%; heart failure (HF): 36.1%
versus 13.9% and 24.6%; myocardial infarction:
11.3% versus 4.7% and 7.4%; stroke: 8.9% versus 4.0% and 5.7%; and mortality: 18.5% versus
6.0% and 11.7%, respectively. Within the
DAPA-CKD-like cohort, patients with versus
without T2D or HF had a higher frequency of
adverse outcomes. The DAPA-CKD-like cohort
also had significantly higher annualized perpatient healthcare costs ($39,222/year versus
$19,547/year), hospital admission rate (0.55/
year versus 0.20/year) and outpatient specialist
visit rate (7.55/year versus 6.74/year) versus the
lowest UACR category.
Conclusion: The significant adverse renal and
cardiovascular outcomes observed, particularly
in the DAPA-CKD-like cohort, represent a substantial burden resulting in increased mortality,
HCRU and costs, demonstrating the need for
additional treatment options.
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Key Summary Points
The DAPA-CKD trial assessed dapagliflozin
in patients with chronic kidney disease
(CKD) with and without type 2 diabetes.
To aid interpretation of the DAPA-CKD
results, renal and cardiovascular
outcomes, plus healthcare resource
utilization (HCRU) and costs, were
assessed in a real-world population
reflective of the DAPA-CKD trial.
Incidence of adverse clinical outcomes
(overall renal composite outcome, heart
failure, myocardial infarction, stroke,
mortality) increased with UACR and was
highest for the DAPA-CKD-like cohort vs.
lower UACR categories.
The DAPA-CKD-like cohort also had
significantly higher annualized perpatient healthcare costs, rates of hospital
admission and rates of outpatient
specialist visits vs. the lowest UACR
category.
The significant adverse renal and
cardiovascular outcomes observed,
particularly in the DAPA-CKD-like cohort,
represent a substantial burden resulting in
increased mortality and HCRU and costs,
demonstrating the need for additional
treatment options.

DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate understanding of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.13365545.
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INTRODUCTION
Chronic kidney disease (CKD), defined as either
abnormalities of kidney structure marked by
damage or decreased function indicated by
declining estimated glomerular filtration rate
(eGFR) present for [ 3 months, is a worldwide
public health problem [1]. The classification of
CKD is based on etiology, eGFR and urine
albumin-to-creatinine ratio (UACR). Patients
are more commonly categorized by eGFR,
ranging from stage 1 (eGFR C 90 ml/min/
1.73 m2), with mild kidney damage, to stage 5
(eGFR \ 15 ml/min/1.73 m2), signifying kidney
failure and usually a need for dialysis or kidney
transplant; however, guideline recommendations state that a patient’s eGFR category should
be combined with UACR to aid staging and risk
stratification. UACR is an important predictor
of risk for disease progression, adverse outcomes
and mortality [1, 2]. Categories range from A1
(UACR \ 30 mg/g) to normal/mildly increased,
to A3 (UACR [ 300 mg/g) and severely
increased [1].
Between 2013 and 2016, an estimated 14.8%
of the US adult population had CKD (stages
1–5), with CKD stage 3 (6.4%) being the most
common [3]. Patients with CKD are at a significantly increased risk of adverse clinical outcomes, including cardiovascular events (e.g.
heart failure [HF]), hospitalization, end-stage
kidney disease (ESKD) and premature death,
which are directly associated with the degree of
CKD severity [1, 4, 5]. CKD is also associated
with substantial mortality, morbidity and
healthcare costs. Medicare spending (excluding
dialysis) for all beneficiaries who had CKD
(12.5%) exceeded $84 billion in 2017, an
increase of 6.3% from 2016 [6]. After combining
an additional $36 billion attributable to ESKD
costs, total Medicare spending on both CKD
and ESKD was over $120 billion, representing
33.8% of the total Medicare fee-for-service
spending [6].
Management of risk factors for CKD progression (e.g., systolic blood pressure and glycated hemoglobin in patients with diabetes) is
key to the treatment of patients with CKD;
however, there remains a lack of dedicated
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evidence-based treatment options that slow
disease progression and improve patient outcomes. Trials of renin-angiotensin–aldosterone
system (RAAS) inhibitors have demonstrated
reno-protective effects, such as a reduction in
the risk of doubling of serum creatinine and the
development of ESKD in patients with type 2
diabetes (T2D) and nephropathy [7–9],
although evidence in patients without T2D has
been scarce [10]. There has been a lack of success in developing newer therapies on top of
RAAS inhibitors as current standard of care to
delay progression and improve outcomes in
patients with or without T2D.
Sodium-glucose co-transporter 2 inhibitors
have demonstrated significant cardiorenal benefits in previous trials in patients with T2D
[11, 12] as well as cardiovascular benefits in
patients with HF with reduced ejection fraction
in the presence or absence of diabetes [13–15].
In the Dapagliflozin and Prevention of Adverse
Outcomes in CKD (DAPA-CKD) trial, which
assessed the effect of dapagliflozin on kidney
outcomes and mortality in patients with CKD
and elevated UACR (200–5000 mg/g), dapagliflozin significantly reduced the composite of
risk of CKD progression, ESKD, renal or cardiovascular death (hazard ratio [HR], 0.61 [95%
confidence interval [CI] 0.51–0.72]), cardiovascular death or HF hospitalization (HR, 0.71
[95% CI 0.55–0.92]) and all-cause mortality
(HR, 0.69 [95% CI 0.53–0.88]) in patients with
or without T2D [16].
To understand the CKD disease burden at a
population level in a routine clinical practice
setting, and to aid clinical implementation of
the DAPA-CKD results, we report real-world
clinical outcomes and healthcare resource utilization (HCRU) from the Henry Ford Health
System (HFHS) in a patient population that
meets the DAPA-CKD trial criteria and compare
these to patients with similar CKD staging but
lower UACR.

METHODS
Study Design
This was a retrospective, longitudinal, observational study evaluating information from electronic healthcare records (EHRs) and an
administrative data set of the HFHS. The HFHS
is a large integrated US healthcare delivery system that provides almost 950,000 patients with
care annually, with 4.2 million outpatient
encounters, 100,000 surgeries and 113,000
hospitalizations. The HFHS operates in five
regions throughout South-East Michigan, providing data that can be utilized to examine realworld outcomes of patients with CKD across
different populations, facilitating the interpretation and practical implications of clinical
studies [17]. The study was approved by the
HFHS Institutional Review Board.
Patients
Patients from HFHS data (2006–2016) were
identified with CKD stages 2–4 (eGFR 25–75 ml/
min/1.73 m2, calculated using the Chronic
Kidney Disease Epidemiology Collaboration
[CKD-EPI] equation) and UACR (0–5000 mg/g).
The index event was the first qualifying eGFR. A
second eGFR C 90 days after index was used to
confirm chronicity of the disease and to rule out
acute kidney injury. Additional inclusion criteria included being C 18 years old and having C 1 UACR measurement (0–5000 mg/g)
within 6 months pre- and post-index. Exclusion
criteria included: history of kidney transplant or
dialysis any time pre-index date or within
6 months post-index date, progression to CKD
stage 5 within 6 months of the index date, no
UACR measurement or UACR [ 5000 mg/g
during baseline (the 12 months pre-index), and
any history or diagnosis 6 months post index of
type 1 diabetes, polycystic kidney disease, lupus
nephritis or anti-neutrophil cytoplasmic antibody nephritis. Each patient was followed for
5 years after the index date. The study timeline
is presented in Fig. 1.
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Fig. 1 Study timeline. eGFR estimated glomerular ﬁltration rate, HCRU healthcare resource utilization
Assessments
Primary outcomes were renal composite outcomes, which consisted of progression to CKD
stage 5, onset of dialysis, kidney transplant and/
or C 50% sustained decline in eGFR (second C 50% decline measured at least 28 days
apart) as well as cardiovascular outcomes and
mortality. Cardiovascular outcomes were comprised of myocardial infarction (MI), hospitalization for MI, stroke, hospitalization for stroke,
HF, and hospitalization for HF. Any hospitalizations for the given outcome during
the 5 years of follow-up were counted. All-cause
mortality during the follow-up period was also
investigated, and all clinical outcomes were
evaluated for up to 5 years follow-up
(cumulative).
Secondary outcomes included HCRU and
costs, comprising all-cause hospital admissions,
inpatient days, emergency department visits,
outpatient primary care visits, outpatient specialist visits and total outpatient visits. Data
extracted from the administrative database were
coded specifically for each of these encounter
types. Outcomes were evaluated by rate/year,
except inpatient days, which were calculated by
length of stay. Cumulative HCRU outcomes
were based on follow-up time. Patients were
censored on date of death, last contact with the
health system or on December 31, 2018. Allcause costs of care were annualized charges.
Billing data on all patient charges were used as
proxy for costs of care; medication costs were
not available.
Patients were stratified into three cohorts by
UACR:
0–29 mg/g,
30–199 mg/g
and

200–5000 mg/g, the last comprising the DAPACKD-like cohort. Analyses in the DAPA-CKDlike cohort were additionally stratified by baseline HF and T2D. Outcomes were additionally
assessed by eGFR and UACR categories.
Statistical Analysis
Categorical variables were presented as count
and percentage of patients in each category;
continuous variables were summarized by providing the means and standard deviations.
Descriptive statistics provided the overall characteristics of the study population at baseline.
Chi-square statistics were used to compare the
clinical outcomes in the three study cohorts.
Analysis of variance was used to compare the
mean HCRU outcomes between groups, based
on annualized utilization using the duration of
follow-up for each patient.

RESULTS
Patients
The source population included 22,251
patients; applying the eligibility criteria resulted
in a final study population of 6557 (Fig. 2).
Notably, 9702 of 22,251 (43.6%) patients
meeting the eGFR criteria were excluded from
the study as they had no available UACR measurement. Patient baseline characteristics and
demographics are presented in Table 1. Notably,
the
DAPA-CKD-like
cohort
(UACR
200–5000 mg/g) had the highest baseline burden of comorbid HF and history of

1356

Adv Ther (2021) 38:1352–1363

Fig. 2 Patient attrition diagram. eGFR estimated glomerular ﬁltration rate, ESKD end-stage kidney disease, PKD polycystic
kidney disease, T1D type 1 diabetes, UACR urine albumin-to-creatinine ratio. aBaseline deﬁned as 12 months pre-index date
cardiovascular events. Baseline characteristics
according to T2D status and HF are shown in
Table S1 and Table S2, respectively.
Clinical Outcomes at 5-Year Follow-up
Across all adverse clinical outcomes assessed,
increased risk was observed in patients with
increased UACR, with the highest incidence in
the DAPA-CKD-like cohort versus patients in
lower UACR categories (Fig. 3a); notable outcomes included the overall renal composite
outcome (26.0% in the DAPA-CKD-like cohort
vs. 5.8% in the UACR 30–199 mg/g category
and 2.2% in the UACR 0–29 mg/g category) and
all-cause mortality (18.5% in the DAPA-CKDlike cohort vs. 11.7% in the UACR 30–199 mg/g
category and 6.0% in the UACR 0–29 mg/g
category). Within the DAPA-CKD-like cohort,
patients with T2D or HF had a numerically
higher frequency of adverse outcomes than
patients without these comorbidities. There
were no statistical differences between those
with and without T2D. Patients with HF had
statistically increased incidences of the overall
renal composite, MI and all-cause mortality
outcomes compared to patients without HF
(Fig. 3b, c).

Healthcare Resource Utilization and Costs
at 5-Year Follow-up
Costs of care per patient in the DAPA-CKD-like
cohort were significantly higher and more than
double that of the lowest UACR category (UACR
0–29 mg/g), at $39,222/year versus $19,547/
year, respectively (Fig. 4a). Hospital admission
rates for patients in the DAPA-CKD-like cohort
were almost three times higher than those for
patients in the lowest UACR category (0.55/year
vs. 0.20/year, respectively; Fig. 4a). Additionally, length of stay was over 3 times higher in
the DAPA-CKD-like cohort than in the lowest
UACR category (Fig. 4a).
In the DAPA-CKD-like cohort, HCRU and
costs were comparable between patients with
and without T2D (Fig. 4b). However, patients
with baseline HF had significantly increased
acute and ambulatory care needs and costs
versus patients without HF (Fig. 4c). This burden is already evident in the early stages of
CKD; more granular outputs according to the
Kidney Disease: Improving Global Outcomes
2012 categorization are reported in the supplementary material (Tables S3 and S4). Overall,
costs increased across the ascending UACR categories (from 0–29 mg/g to 30–199 mg/g up to
200–5000 mg/g). This was seen both for the
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Table 1 Baseline demographicsa and characteristics stratiﬁed by UACR category
0–29 (n = 4331)b

30–199 (n = 1354)b

200–5000 (n = 872)b

Total (N = 6557)c

P value

Male

1885 (62.2)

679 (22.4)

466 (15.4)

3030 (46.2)

\ 0.0001

Female

2446 (69.4)

675 (19.1)

406 (11.5)

3527 (53.8)

63.1 (8.2)

63.3 (8.7)

61.4 (9.4)

62.9 (8.5)

\ 0.0001

2

2691 (73.2)

676 (18.4)

309 (8.4)

3676 (56.1)

\ 0.0001

3a

1275 (62.6)

466 (22.9)

297 (14.6)

2038 (31.1)

3b

337 (45.7)

186 (25.2)

215 (29.1)

738 (11.3)

4

UACR category (mg/g)
Gender, n (%)

Age (years), mean (SD)
CKD stage, n (%)d

28 (27.7)

26 (24.8)

51 (48.6)

105 (1.6)

eGFR (ml/min/1.73 m2), mean (SD)

61.5 (10.7)

58.0 (12.3)

52.8 (14.2)

59.6 (11.9)

\ 0.0001

UACR (mg/g), mean (SD)

10.5 (6.8)

76.8 (41.3)

1086.8 (1040.5)

167.3 (524)

\ 0.0001

Serum potassium, n

3966

1245

801

6012

4.3 (0.4)

4.4 (0.5)

4.4 (0.5)

4.3 (0.4)

3036

916

516

4468

7.3 (1.4)

7.8 (1.8)

8.2 (2.0)

7.5 (1.6)

T2D

3828 (88.4)

1196 (88.3)

752 (86.2)

5776 (88.1)

NS

Heart failure

225 (5.2)

120 (8.9)

122 (14.0)

467 (7.1)

\ 0.001

T2D and heart failure

205 (4.7)

115 (8.5)

115 (13.2)

435 (6.6)

\ 0.001

Hypertension

3130 (72.3)

987 (72.9)

670 (76.8)

4787 (73.0)

\ 0.05

Hypertensive nephropathy

156 (3.6)

111 (8.2)

152 (17.4)

419 (6.4)

\ 0.001

Glomerulonephritis

11 (0.3)

7 (0.5)

25 (2.9)

43 (0.7)

\ 0.001

mmol/l, mean (SD)
HbA1c, n
%, mean (SD)

\ 0.05
\ 0.001

Comorbidities, n (%)e

Myocardial infarction

53 (1.2)

29 (2.1)

33 (3.8)

115 (1.8)

\ 0.001

Stroke

45 (1.0)

18 (1.3)

21 (2.4)

84 (1.3)

\ 0.01

Peripheral artery disease

152 (3.5)

71 (5.2)

59 (6.8)

282 (4.3)

\ 0.001

Coronary artery disease

533 (12.3)

174 (12.9)

127 (14.6)

834 (12.7)

NS

Dyslipidemia

2513 (58.0)

723 (53.4)

441 (50.6)

3677 (56.1)

\ 0.001

CKD chronic kidney disease, eGFR estimated glomerular ﬁltration rate, HbA1c glycated hemoglobin, NS not signiﬁcant, SD standard deviation, T2D type 2
diabetes, UACR urine albumin-to-creatinine ratio
a
Baseline deﬁned as 12 months pre-index date
b
Percentages calculated using the total for that row as denominator
c
Percentages calculated using the total for that column
d
CKD stages 2, 3a, 3b and 4: eGFR 60–75, 45 to \ 60, 30 to \ 45 and 25 to \ 30 ml/min/1.73 m2, respectively
e
Comorbidities based on diagnoses codes for clinical encounters. Signiﬁcance calculated using chi-square analysis for categorical variables and analysis of
variance for mean age

overall UACR groups (Fig. 4a) and when
patients were categorized further by eGFR category; costs also increased with declining eGFR
level (Table S4A). An exception was the highest
UACR category studied (200–5000 mg/g), where
costs were lower in the subgroup of patients
with eGFR 25– \ 30 ml/min/1.73 m2, although
patient numbers were relatively low for this
eGFR category (Table S4A).

DISCUSSION
In this study, a large population of patients with
CKD was stratified into three cohorts by UACR,
with the highest range (200–5000 mg/g) comprising the DAPA-CKD-like cohort. The incidences of adverse renal, cardiovascular and
mortality outcomes were high overall, but were
highest in the DAPA-CKD-like cohort compared
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with patients in lower UACR categories; this was
seen in both patients with and without T2D as
well as those with and without HF. HCRU and
costs were also higher in the DAPA-CKD-like
cohort compared with the lower UACR categories. The impact of UACR category on HCRU
and costs of care has not been previously
reported for patients with CKD.
Previous renal outcome trials in CKD have
failed to demonstrate a significant benefit from
the tested therapeutic intervention in all-cause
mortality, despite a reduction in CKD progression [8, 9, 12, 18]. The overall renal composite
outcome and all-cause mortality in this study
(26.0% and 18.5%, respectively) were notably
increased in the DAPA-CKD-like cohort versus
patients with lower UACR. HCRU and costs of
care increased with UACR category, particularly
in acute care. While this increase was seen with
disease progression, there was a high clinical
burden even at the early stages of CKD, suggesting a need for early intervention to slow
disease progression.
These results highlight the current unmet
need in a contemporary real-world population
stratified by UACR, particularly for the cohort
with UACR reflective of the DAPA-CKD trial
inclusion
criteria.
However,
widespread
undertesting of UACR limits appropriate risk
stratification of patients with CKD, which could
result in delaying intervention or treatment.
Low UACR testing in patients with CKD is not
unique to the HFHS database; in a cohort study
of EHRs from two large US healthcare systems
(the Center for Kidney Disease Research, Education, and Hope [CURE-CKD] registry),
approximately 90% of high-risk patients with
CKD who should have been tested did not have
UACR laboratory measurements available [19].
Strengths
The major strengths of this study include the
large and diverse study population and the
extensive follow-up period. The HFHS database
used in this analysis captures high-quality data
via its EHR, including a broad spectrum of relevant laboratory test results and longitudinal
datapoints. Inputs made at the point of care are

stored as structured data fields, and patients
have a lifetime medical record number that is
used across all content areas. All outpatient,
emergency room, and inpatient encounters and
procedures are captured using International
Classification of Diseases 9th or 10th revision
codes, and Current Procedural Terminology
version 4 procedural codes. The strength of the
database is also shown by the numerous publications from HFHS, including in journals such
as Cancer Epidemiology, Biomarkers and Prevention, Journal of Obstetrics and Gynecology Canada
and the American Journal of Otolaryngology.
UACR is not captured or reported well in
many databases and as a result patient outcomes stratified by UACR category are often not
available in the literature. By contrast, the
source population utilized in this study included a high percentage of patients with UACR
data compared with other studies, such as the
study by Tuttle et al. [19]. The present study
adds to the literature surrounding the clinical
and financial burden associated with different
UACR categories and aids in the understanding
of the potential role that new therapies can play
in addressing the residual risk in patients with
CKD managed in a real-world setting.
The importance of UACR to consider as an
additional risk marker as well as eGFR in
patients with CKD can be shown by the findings
of the present study. Although the percentage
of patients with UACR in the highest risk category (200–5000 mg/g) was higher in the later
CKD stages versus the earlier stages, there were
still 8.4% of patients with CKD stage 2 and
14.6% in the highest UACR category. Similarly,
in the DAPA-CKD trial (all patients with UACR
200–5000 mg/g at baseline), although the
majority of patients had in the lowest ranges
studied, 10.9% and 10.2% of patients in the
dapagliflozin and placebo groups, respectively,
had eGFR in the highest range studied
(60–75 ml/min/1.73 m2, roughly equivalent to
CKD stage 2) [16].
Limitations
This is a study based on real-world data that
were collected observationally in the usual
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3 Clinical outcomes at 5 years. CKD chronic kidney
disease, eGFR estimated glomerular ﬁltration rate, HF
heart failure, MI myocardial infarction, NS not signiﬁcant,
T2D type 2 diabetes, UACR urine albumin-to-creatinine
ratio. aSecond eGFR [ 50% decline at least 28 days apart.
Cardiac outcomes (MI, stroke and HF) include patients
with any encounter during 5 years of follow-up. Hospitalization outcomes include patients with a hospitalization
for the given outcome during 5 years of follow-up.
Statistical signiﬁcance of patient outcomes calculated using
chi-square analysis. *P \ 0.05, **P \ 0.01, ***P \ 0.001,
****P \ 0.0001. Axes cropped at 40% to enhance visual
assessment. Patients were excluded if they had no eGFR or
clinical encounter in the ﬁfth year of follow-up

b Fig.

clinical setting through electronic medical
records or administrative claims, in contrast to
the clinical trial setting. The DAPA-CKD trial
composite primary outcome component of
death from cardiovascular and renal causes
could not be analyzed in the present study
population due to lack of data availability;
however, all-cause mortality was investigated.
Comprehensive assessment of adherence to
standard of care was also not possible because of
the lack of availability of baseline medication
status. Although the cost of medications was
not available, we reported on healthcare costs
stratified by UACR measurement, which have
not previously been reported in the literature.
Findings of this study are based on a single
healthcare system and so may not be generalizable to the entire US population; additionally,
HCRU and associated costs of care may differ by
region and healthcare systems within the US
and compared with Medicare. Although utilization of HCRU outside of the health care
system was not available for this study, the
patients in this analysis had long-term care
within the health system; hence, most of the
HCRU is likely captured. Additionally, administrative data are subject to potential coding
error and are not collected for research.
The majority of the study population had
T2D (88.1%), which may limit comparisons to
previous studies of patients with CKD that had
higher proportions of patients without diabetes
[2]. Although this may be reflective of clinical
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[19], this may also limit applicability of results
to the DAPA-CKD trial, which enrolled 32.5% of
patients without T2D [20]. However, it should
be noted that a trend for similar clinical and
HCRU/cost outcomes between patients with
and without T2D was observed in the present
study.
As a selection criterion, UACR measurement
may have enriched the study population with a
higher burden of comorbidities due to the
increased likelihood of UACR monitoring at
baseline. In addition, a considerable proportion
of the source population did not have a UACR
measurement during baseline, an exclusion
criterion that restricted the size of the final
study population. The cohort without comorbid
T2D or HF included in this study may not be
fully representative of real-world patients with
CKD, but may simply be reflective of the population tested for UACR in clinical practice
because of the limited UACR testing undertaken
in the overall HFHS database/population. Given
the importance of UACR in disease staging [1],
and the association of UACR with adverse outcomes demonstrated in this analysis, more
needs to be done to increase the frequency of
UACR testing across all patients with and at risk
of CKD.

CONCLUSIONS

Fig. 4 Healthcare resource utilization and costs. eGFR
estimated glomerular ﬁltration rate, HF heart failure, NS
not signiﬁcant, T2D type 2 diabetes, UACR urine
albumin-to-creatinine ratio. Utilization rates are the total
observed utilization divided by follow-up time and
reported as an annual rate. Healthcare resource utilization/costs cover the entire follow-up period. Annualized
charges are per patient. *P \ 0.05, **P \ 0.01,
***P \ 0.001, ****P \ 0.0001. Statistical signiﬁcance calculated using analysis of variance
practice where, if done, UACR testing is more
likely to be conducted in patients with T2D

CKD is associated with a high burden of disease,
mortality and healthcare costs. This study
aimed to aid clinical interpretation and implementation of the DAPA-CKD trial results by
assessing the residual renal, cardiovascular and
mortality risk, along with the HCRU and costs,
in a contemporary real-world CKD population.
Results of this analysis demonstrated significant and increased adverse renal, cardiovascular and mortality outcomes among patients
with CKD stages 2–4 with elevated UACR (the
DAPA-CKD-like cohort) as well as increased
HCRU and costs compared with those in lower
UACR categories. This was seen in patients both
with and without comorbid T2D or HF,
although in general patients with T2D or HF
had a numerically higher frequency of adverse
outcomes than patients without these
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comorbidities. There were no statistical differences in clinical outcomes between those with
and without T2D, and increased incidences
between those with and without HF. Patients
with elevated UACR and baseline HF had significant increases in annual rate of hospital
admissions, length of hospital stay, rate of
emergency department visits, rate of outpatient
specialist visits, rate of total outpatient visits
and annualized charges compared with patients
without HF.
Along with a need for more standardized
UACR testing, there remains a need for more
proactive management and additional therapies
addressing the substantial residual risks for
patients with CKD—particularly patients with
elevated UACR, reflective of the DAPA-CKD trial
cohort. This will help address the burden of
CKD progression and its attendant adverse cardiovascular profile with escalating healthcare
costs, as well as improve outcomes in the
patient population with kidney disease. Full
cost-effectiveness analysis based on the DAPACKD trial outcomes would be beneficial as
future research and, together with the assessment of the residual risk presented here, would
further aid in healthcare implementation
planning.
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